ストックスクリーナーアプリを入手
0.39
4.88%
-0.02
アフターアワーズ：
.39
前日終値:
$0.41
開ける：
$0.4161
24時間の取引高:
1.50M
Relative Volume:
0.08
時価総額：
$25.15M
収益：
$1.16M
当期純損益:
$-37.28M
株価収益率:
-0.60
EPS:
-0.65
ネットキャッシュフロー:
$-33.81M
1週間 パフォーマンス:
-20.41%
1か月 パフォーマンス:
+144.06%
6か月 パフォーマンス:
-78.69%
1年 パフォーマンス:
-71.11%
1日の値動き範囲:
$0.3832
$0.4161
1週間の範囲:
$0.3101
$0.536
52週間の値動き範囲:
$0.1406
$3.5299
Glycomimetics Inc Stock (GLYC) Company Profile
名前
Glycomimetics Inc
セクター
電話
240-243-1201
住所
9708 MEDICAL CENTER DRIVE, ROCKVILLE, MD
Glycomimetics Inc Stock (GLYC) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-07-26 | ダウングレード | TD Cowen | Buy → Hold |
| 2023-12-22 | 開始されました | CapitalOne | Overweight |
| 2021-11-12 | アップグレード | Jefferies | Hold → Buy |
| 2019-11-14 | 開始されました | ROTH Capital | Buy |
| 2019-08-05 | ダウングレード | Jefferies | Buy → Hold |
| 2019-08-05 | ダウングレード | Piper Jaffray | Overweight → Neutral |
| 2019-08-05 | ダウングレード | SunTrust | Buy → Hold |
| 2019-04-12 | 開始されました | Piper Jaffray | Overweight |
| 2018-12-18 | 開始されました | H.C. Wainwright | Buy |
| 2016-07-26 | 開始されました | SunTrust | Buy |
| 2015-03-17 | 繰り返されました | Stifel | Buy |
すべてを表示
Glycomimetics Inc (GLYC) 最新ニュース
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALTR, PFIE, GLYC on Behalf of Shareholders - Marketscreener.com
What Do Wall Street Analysts Think About GlycoMimetics Inc (NASDAQ: GLYC) Stock? - Stocks Register
INVESTIGATION ALERT: The M&A Class Action Firm Investigates the Merger of GlycoMimetics, Inc.GLYC - PR Newswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates USAP, ALTR, GLYC on Behalf of Shareholders - The Malaysian Reserve
GlycoMimetics’ Acquisition of Crescent Biopharma - Global Legal Chronicle
GlycoMimetics, Canaan, PayPal: 3 Stocks Retail Is Most Bullish On Today - MSN
GLYCOMIMETICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of GlycoMimetics, Inc.GLYC - Business Wire
3 Penny Stocks to Watch Now, 10/31/24 - TipRanks
GlycoMimetics Announces Merger Agreement with Crescent Biopharma: A Look at the Details - Defense World
GlycoMimetics To Acquire Crescent Biopharma - FinSMEs
GlycoMimetics soars on news of M&A deal with Crescent Biopharma - The Pharma Letter
GlycoMimetics Announces Merger with Crescent Biopharma - Yahoo Finance
GlycoMimetics Insider Confidence Rewarded, Stock Hits US$11m Market Cap - Simply Wall St
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PFIE, CPTN, GLYC, ARC on Behalf of Shareholders - GlobeNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PFIE, CPTN, GLYC, ARC on Behalf of Shareholders - GlobeNewswire Inc.
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Profire Energy, Inc. (Nasdaq – PFIE), Cepton, Inc. (Nasdaq – CPTN), GlycoMimetics, Inc. (Nasdaq – GLYC), ARC Document Solutions, Inc. (NYSE – ARC) - ForexTV.com
Gold Gains 1%; Phillips 66 Shares Fall After Q3 Results - Benzinga
GlycoMimetics Stock Triples To Become Top Gainer On Crescent Biopharma Merger Deal: Retail Goes Wild - Barchart
GlycoMimetics Shares Are Soaring Tuesday: Here's Why - Benzinga
Crescent Inks Oncology Merger With $200M In Private Funding - Law360
TSX Composite Weight Index (TXCE) QuotePress Release - The Globe and Mail
GlycoMimetics Agrees to Acquire Crescent Biopharma - MarketWatch
Crescent rolls up to Glycomimetics merger, $200M in new bread - BioWorld Online
Shareholder Alert: Ademi LLP Investigates Whether GlycoMimetics, Inc. is Obtaining a Fair Price for Its Public Shareholders - Business Wire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PFIE and GLYC on Behalf of Shareholders - Marketscreener.com
TSX 60 ESG Index (TSXE) QuotePress Release - The Globe and Mail
US Stocks Mixed; McDonald's Posts Upbeat Earnings - Benzinga
TSX Renewable and Clean Tech Index (TXCT) QuotePress Release - The Globe and Mail
Crescent inks GlycoMimetics merger, securing Nasdaq listing and $200M for hot cancer program - Fierce Biotech
GlycoMimetics enters acquisition agreement with Crescent Biopharma - MSN
Rockville biotech GlycoMimetics to be acquired - The Business Journals
GLYC Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of GlycoMimetics, Inc. Is Fair to Shareholders - Business Wire
GlycoMimetics skyrockets on buyout deal - MSN
GlycoMimetics Agrees to Be Taken Private by Crescent Biopharma - MarketWatch
Glycomimetics Shares Fall After Leukemia Treatment Trial Misses Key Goal - MarketWatch
GlycoMimetics to acquire Crescent Biopharma in a strategic merger - Investing.com
GlycoMimetics Enters Into Acquisition Agreement With Crescent Biopharma - Business Wire
GlycoMimetics Announces National Cancer Institute Phase 2/3 Study of Uproleselan Did Not Meet Primary Endpoint - StockTitan
S&P 500 Energy [Sector] (SREN) QuotePress Release - The Globe and Mail
GlycoMimetics (NASDAQ:GLYC) Now Covered by StockNews.com - Defense World
Analytical Lens: Exploring GlycoMimetics Inc (GLYC)’s Financial Story Through Ratios - The Dwinnex
TD Cowen downgrades GlycoMimetics Inc (GLYC) rating to a Hold - Knox Daily
Renaissance Technologies LLC Buys 685,151 Shares of GlycoMimetics, Inc. (NASDAQ:GLYC) - Defense World
10% Owner Invus Public Equities, L.P. sale 260,873 shares of GlycoMimetics Inc [GLYC] - Knox Daily
GLYC Stock on the Rise: A Promising Investment - The InvestChronicle
Financial Fitness Check: Examining GlycoMimetics Inc (GLYC)’s Key Ratios - The Dwinnex
GlycoMimetics stock plunges to 52-week low of $0.14 - Investing.com
GlycoMimetics stock plunges to 52-week low of $0.14 By Investing.com - Investing.com South Africa
Balance Sheet Insights: GlycoMimetics Inc (GLYC)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
GlycoMimetics Inc [GLYC] Records 50-Day SMA of $0.1817 - Knox Daily
Glycomimetics Inc (GLYC) 財務データ
収益
当期純利益
現金流量
EPS
Glycomimetics Inc (GLYC) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Invus Public Equities, L.P. | 10% Owner |
Aug 07 '24 |
Sale |
0.18 |
61,488 |
11,197 |
6,578,438 |
| Invus Public Equities, L.P. | 10% Owner |
Aug 05 '24 |
Sale |
0.19 |
164,523 |
30,996 |
6,695,658 |
| Invus Public Equities, L.P. | 10% Owner |
Aug 06 '24 |
Sale |
0.18 |
55,732 |
10,188 |
6,639,926 |
| Invus Public Equities, L.P. | 10% Owner |
Aug 02 '24 |
Sale |
0.20 |
286,200 |
57,354 |
6,860,181 |
| Invus Public Equities, L.P. | 10% Owner |
Aug 01 '24 |
Sale |
0.22 |
63,564 |
13,743 |
7,146,381 |
| Invus Public Equities, L.P. | 10% Owner |
Jul 30 '24 |
Sale |
0.22 |
756,835 |
167,185 |
7,209,945 |
| Invus Public Equities, L.P. | 10% Owner |
Jul 29 '24 |
Sale |
0.24 |
363,949 |
85,637 |
7,966,780 |
| Invus Public Equities, L.P. | 10% Owner |
Jul 26 '24 |
Sale |
0.24 |
258,335 |
62,440 |
8,330,729 |
| Rock Edwin | Chief Medical Officer |
Jun 20 '24 |
Buy |
0.25 |
190,000 |
48,108 |
565,403 |
| Rock Edwin | Chief Medical Officer |
Jun 21 '24 |
Buy |
0.27 |
115,000 |
30,716 |
680,403 |
2.02%
0.47%
大文字化:
|
ボリューム (24 時間):